Vir Biotechnology Secures EMA Support for Chronic Hepatitis Delta Treatments tobevibart and elebsiran

Vir Biotechnology Advances Treatments for Chronic Hepatitis Delta with EMA Support

Vir Biotechnology, Inc. has received a significant endorsement from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) regarding the orphan drug designation for its promising treatments, tobevibart and elebsiran. These treatments are specifically aimed at addressing chronic hepatitis delta (CHD), a severe liver disease caused by the hepatitis delta virus. Currently, CHD remains a major health concern, as it lacks approved treatment options in the United States and faces limited therapeutic alternatives in Europe and globally. This positive opinion from the EMA marks a critical step toward enhancing the landscape of treatment options available for patients suffering from this debilitating condition.

The EMA's favorable assessment is bolstered by encouraging preliminary data from the Phase 2 SOLSTICE trial, which investigates the safety, tolerability, and efficacy of tobevibart, both as a standalone treatment and in combination with elebsiran. The trial's 24-week results are set to be presented at the upcoming AASLD The Liver Meeting® on November 18 in San Diego, where Vir Biotechnology aims to showcase its advancements in treating CHD. Mark Eisner, M.D., M.P.H., the company’s Chief Medical Officer, underscores the urgency for new therapies in light of CHD's association with severe liver complications, including cancer and increased mortality risk. The EMA’s conclusions will now be reviewed by the European Commission, which has the authority to grant the orphan drug designation, offering several incentives such as scientific advice, fee reductions, and a decade of market exclusivity upon approval.

In a parallel development, the U.S. Food and Drug Administration (FDA) has granted fast track designation for the combination treatment of tobevibart and elebsiran, further accelerating the development timeline for this critical intervention. This designation is particularly significant as it targets serious conditions with recognized unmet medical needs. Vir Biotechnology has scheduled an investor conference call for November 19, 2024, where company executives will provide further insights into the ongoing trial and outline future strategic plans. The PROMISE of these treatments represents a beacon of hope for patients grappling with CHD and reflects Vir Biotechnology's commitment to addressing critical gaps in the treatment of liver diseases.